Andros Pharmaceuticals Co., Ltd.

About Us

Milestones

2018

  • President Ae-June Wang received the Excellence in Management Award at the 7th Woman Elite Entrepreneurs Competition.
  • Start of phase 2 clinical study of APC101.
  • Received Taiwan FDA licenses for 2% and 5% iMinos Solution.
  • The PIC/s GMP facility passed TFDA audit inspection of GMP and GDP.

2017

  • Established subsidiary Andros Pharmaceuticals Pty Ltd in Australia
  • Received Taiwan FDA license for LALP Cream (site change).

2016

  • Received Innovative Product Award from Hsinchu Science Park for “Liposomal DNA Repairing Enzyme.”
  • Received Small Business Innovation Research (SBIR) Award for the development of “topical anesthetic new dosage form” project.
  • PIC/s GMP certified for solution production.

2015

  • PIC/s GMP certified for cream/gel production, certificate no. (AP)0445117.
  • Start of phase 1 clinical study of APC101.
  • Received USFDA approval of Phase 1 clinical study of APC101.
  • The total paid-in capital was increased to 243 million NTD after the fifth round of cash capital increase.
  • The total paid-in capital was increased to 213 million NTD after the fourth round of cash capital increase.

2014

  • Approval of capital funded SBIR project by Ministry of Economic Affairs with total budget of 9.65 million NTD.
  • Approval of capital funded project by Taipei City Government with total budget of 5.45 million NTD.

2013

  • Approved by MOEA according to the "Biotech and New Pharmaceutical Development Act" as a Biotechnical and New Pharmaceuticals Company.
  • The total paid-in capital was increased to 150 million NTD after the third round of cash capital increase.
  • Approval of capital funded project by Taipei City Government with total budget of 4.7 million NTD.
  • Relocated to Hsinchu Biomedical Science Park.

2012

  • Established branch office at Hsinchu Biomedical Science Park.
  • The total paid-in capital was increased to 100 million NTD after the second round of cash capital increase.

2011

  • Received 12 million NTD of Small Business Innovation Research (SBIR) grant from Ministry of Economic Affairs (MOEA) for the development of “topical anesthetic new dosage form” project.

2010

  • Approved by the Ministry of Science and Technology (MOST) for the relocation to Hsinchu Biomedical Science Park (HBSP).
  • The total paid-in capital was increased to 55 million NTD after the first round of cash capital increase.

2009

  • Exclusive technology transfer of "non-viral gene carrier technology" and 11 related patents from ITRI.

2008

  • Established office and laboratory in ITRI incubation center.
  • Andros Pharmaceuticals was established with a capital of 30 million NTD.